title: Triple anti-TNF-alpha therapy in early sepsis: a preliminary report.
abstract: Ten of 26 patients with sepsis were given a combination of dexamethasone (0.15 mg/kg, intravenously, once on admission), colchicine (0.5 mg, orally, daily, for 3 days) and pentoxifylline (DCP) (400 mg, orally, daily, for 3 days), together with best medical therapy. Serum tumour necrosis factor-alpha (TNF-alpha) levels were undetectable at 24 h compared with about 4 IU/ml (mean) in 16 similar control patients who were not given DCP (P < 0.06). Although the clinical course in the two groups was not significantly different, this simple, well-tolerated and inexpensive regimen should be further evaluated as a possible means of preventing the deleterious effects of TNF-alpha in sepsis.
authors.affiliation: Department of Medicine A, Kaplan Medical Center, Rehovot, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Schattner
authors.forename: I
authors.initials: I
authors.lastname: el-Hador
authors.forename: T
authors.initials: T
authors.lastname: Hahn
authors.forename: Z
authors.initials: Z
authors.lastname: Landau
mesh_terms: D000208:Acute Disease; D003078:Colchicine / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000009:adverse effects / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D003907:Dexamethasone; D010431:Pentoxifylline; D003078:Colchicine